Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
Interferon alfa-2b for decompensated liver disease caused by either chronic hepatitis B or C: preliminary results of
M Dimopoulou1, K Fafoutis, K Basiliou
1State Department of Medicine, Hippokration Hospital, Athens, Greece.
Abstract:
This pilot study was designed to assess the tolerance and effectiveness of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B (n = 7) or C (n = 5). Preliminary results suggest that patients may benefit from small doses of interferon (improvement in liver function tests and reduction in alanine aminotransferase), although the decreased tolerance and dose dependent increase in side effects in these patients with liver disease underlines the need for close follow up and the dose adjustment of interferon treatment.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Chronic Kidney Disease I: Introduction
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History

